(Q38364834)

2 September 2017

1 reference

title

Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? (English)

1 reference

2 September 2017

0 references

2

1 reference

2 September 2017

Iria Grande

1

0 references

publication date

1 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

29

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

221-227

1 reference

The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Mixed states in DSM-5: implications for clinical care, education, and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

New treatment guidelines for acute bipolar mania: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Critical issues on the use of network meta-analysis in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Antipsychotic switching in bipolar disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Adjunctive treatment of acute mania: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Polypharmacy and bipolar disorder: what's personality got to do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Lithium: still a major option in the management of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0235-1

Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

12 December 2020

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

1 reference

12 December 2020

Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol

1 reference

12 December 2020

A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania

1 reference

12 December 2020

Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group

1 reference

12 December 2020

Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder

1 reference

12 December 2020

Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd).

1 reference

12 December 2020

Acute mania: haloperidol dose and augmentation with lithium or lorazepam

1 reference

12 December 2020

A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.

1 reference

12 December 2020

The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study

1 reference

12 December 2020

10.1007/S40263-015-0235-1

Identifiers

DOI

1 reference

2 September 2017

1 reference